. TakedaPharma to CoDevelop EnteromeSA Crohn's Disease Candidate EB8018...
. TakedaPharma to CoDevelop EnteromeSA Crohn's Disease Candidate EB8018 httpow.lyX8iW30mliz3 pic.twitter.comVGHPSTUYmL
View ArticleTillotts Pharma AG Pharmaceuticals Healthcare Deals and Alliances Profile...
SummaryTillotts Pharma AG Tillotts a subsidiary of Zeria Pharmaceutical Co Ltd is a healthcare solution provider that develops licenses and markets pharmaceutical products medical devices and...
View ArticleNeovacs SA ALNEV Pharmaceuticals Healthcare Deals and Alliances Profile...
SummaryNeovacs SA Neovacs is a biotechnology company that develops various therapeutic vaccines for the treatment of autoimmune disorders inflammatory diseases and cancers. The company offers TNF...
View ArticleTxCell SA TXCL Pharmaceuticals Healthcare Deals and Alliances Profile Report...
SummaryTxcell SA Txcell is a biotechnology company that develops and innovates cellbased immunotherapy utilizing antigen specific regulatory Tcells. The company provides pipeline products such as...
View ArticleTakeda Enterome collaborate on Crohn's disease candidate
Takeda Pharmaceutical acquired exclusive marketing rights outside the US for Enterome's Crohn's disease candidate EB8018. More
View ArticleMicrobiome Biotech Enterome Signs Deal With Takeda Worth up to 600M
The French biotech Enterome and Takeda are teaming up to fight Crohns disease with a deal worth up to 600M. The two companies will collaborate in the development and commercialization of Enteromes lead...
View ArticleWith $50 Million in Upfront Money Takeda and Enterome DoubleDown on Crohns...
With $50 Million in Upfront Money Takeda and Enterome DoubleDown on Crohn’s Disease httpdlvr.itQpDnLj pic.twitter.comogLmpKvh0o
View ArticleStelaras Efficacy in Crohns Continues to Show in ThreeYear Study
At the 26th United European Gastroenterology Week UEGW congress in Vienna Janssen presented threeyear data from the IMUNITI study which demonstrates the continued efficacy of Stelara ustekinumab in...
View ArticleMedical News Today Can Crohn's disease be fatal
Crohns disease is a longterm condition that affects the gastrointestinal tract. People do not usually die from the disease but it can increase the risk of severe or fatal complications. In this article...
View ArticleJanssens STELARAÂ ustekinumab Demonstrates Sustained Efficacy in Improving...
New study data also confirm efficacy for STELARAÂ ustekinumab in patients who are nave and refractoryintolerant to tumour necrosis factor TNF antagonist treatment The Janssen Pharmaceutical Companies...
View ArticleEnterome and Takeda Enter Licensing CoDevelopment and CoPromotion Agreement...
ENTEROME SAÂa clinicalstage biotech company developing innovative therapies to treat microbiomeassociated diseases with a focus on autoimmune disease and cancer has entered into a global licensing...
View ArticleStelaras Efficacy in Crohns Continues to Show in ThreeYear Study...
Stelara’s Efficacy in Crohn’s Continues to Show in ThreeYear Study httpdlvr.itQpMPDn pic.twitter.comjGIbWSJ1ZY
View ArticleTakeda gets rights to Enterome's Crohn's candidate
Takeda Pharmaceutical Co. Ltd. and Enterome SA entered a codevelopment and copromotion agreement for Enteromes GI disease candidate EB8018 which is in a Phase Ib trial for Crohns disease.
View ArticleArena Pharmaceuticals Inc ARNA Financial and Strategic SWOT Analysis Review...
Arena Pharmaceuticals Inc ARNA Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by...
View ArticleFred Hutchinson Cancer Research Center Pharmaceuticals Healthcare Deals and...
SummaryFred Hutchinson Cancer Research Center Fred Hutchinson a subsidiary of National Comprehensive Cancer Network is a nonprofit organization which conducts research on the prevention diagnose and...
View ArticleuBiome Appoints Dr. Jonathan Braun MD PhD Prominent UCLA PhysicianResearcher...
The leader in microbial genomics appoints pathology expert to its board of scientific advisors.SAN FRANCISCO PRWEB October 25 2018 uBiome the leader in microbial genomics announces the addition of Dr....
View ArticleAevi Genomic Medicine Inc GNMX Pharmaceuticals Healthcare Deals and Alliances...
SummaryAevi Genomic Medicine Inc Aevi formerly Medgenics Inc is a research and development company that discovers and develops novel therapies for pediatric onset and lifealtering diseases.The company...
View ArticleDeciphera Pharmaceuticals LLC DCPH Pharmaceuticals Healthcare Deals and...
SummaryDeciphera Pharmaceuticals LLC Deciphera Pharmaceuticals is a research and development company that develops designs and commercializes kinase inhibiting drugs. The company provides clinical...
View ArticleCD MicroRNA Marks Subtypes with Differing Outcomes
Crohns disease CD one of the primary inflammatory bowel diseases IBD is a chronic inflammatory condition of the gastrointestinal tract...
View ArticleTreating Depression May Mitigate IBD Risk Study Shows
Patients with depression are at increased risk of developing ulcerative colitis and Crohn's disease but treatment with antidepressants may offer some protection. Medscape Medical News
View Article